Markova S
Eksp Med Morfol. 1989;28(2):56-9.
Captopril is the first oral inhibitor of angiotensin-converting enzyme, which has a strong effect on patients with hypertonic states. The influence of the preparation was studied on liver drug-metabolizing enzymic systems of rats in two ways of oral administration-single and a 10-day treatment with a dose of 75 mg/kg. The effect on the levels of microsomal cytochrome B5 and P450 as well as on that of hem was investigated. The activities of some enzymes from the first and second phases of biotransformation were determined. There no changes in the examined parameters 1 h after single oral treatment with 75 mg/kg of captopril. Induction of some of the examined enzymes was observed after a 10-day treatment with 75 mg/kg r. o. of captopril once daily: there was statistically significant elevation of the level of cytochrome P450 as well as of the activity of ethylmorphindelethylase and HA-DPH-cytochrome-C-reductase. The results show that there is probably induction at the first phase of phenobarbital type of drug metabolism.
卡托普利是第一种口服血管紧张素转换酶抑制剂,对高血压患者有强效作用。以两种口服给药方式——单次给药和以75毫克/千克的剂量连续治疗10天,研究了该制剂对大鼠肝脏药物代谢酶系统的影响。研究了其对微粒体细胞色素B5和P450水平以及血红素水平的影响。测定了生物转化第一阶段和第二阶段某些酶的活性。单次口服75毫克/千克卡托普利后1小时,所检测参数无变化。每日一次口服75毫克/千克卡托普利连续治疗10天后,观察到某些被检测酶有诱导作用:细胞色素P450水平以及乙基吗啡脱乙基酶和HA-DPH-细胞色素C还原酶的活性有统计学意义的升高。结果表明,在药物代谢的苯巴比妥类型第一阶段可能存在诱导作用。